<DOC>
	<DOCNO>NCT01179399</DOCNO>
	<brief_summary>Overview Study Design : This phase 1 , multicenter , open-label , multiple-dose , dose-escalation study design evaluate safety , tolerability , pharmacokinetics ( PK ) , antitumor activity TAK-960 patient advance nonhematologic malignancy . This study first administer TAK-960 human . The patient population consist adult nonhematologic malignancy standard treatment longer effective offer curative life-prolonging potential , standard treatment available .</brief_summary>
	<brief_title>Study Orally Administered TAK-960 Patients With Advanced Nonhematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Male female 18 year old Clinical laboratory value specify protocol Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically and/or cytologically confirm diagnosis metastatic , unresectable , advance evaluable nonhematologic malignancy standard treatment available longer effective Radiographically clinically evaluable tumor Suitable venous access studyrequired blood sample Female patient postmenopausal , surgically sterile agree practice 2 effective method contraception abstain heterosexual intercourse Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse Voluntary write consent Willing undergo biopsy procedure ( expansion phase ) Weight least 40 kg Recovered reversible effect prior antineoplastic therapy Grade â‰¤ 1 patient 's baseline value , exclude alopecia Patients meet follow exclusion criterion enrol study : Diagnosis primary central nervous system malignancy carcinomatous meningitis Patient symptomatic brain metastasis . Patients brain metastasis must : stable neurologic status least 2 week follow completion local therapy AND without neurologic dysfunction would confound evaluation adverse event Prior allogeneic bone marrow stem cell transplant Prior therapy treatment specify protocol Female patient lactate positive serum pregnancy test screening period within 3 day first dose TAK960 Myocardial infarction within 6 month first dose TAK960 Any cardiovascular condition value specify study protocol within 6 month first dose TAK960 Infection require systemic antiinfective therapy within 14 day start TAK960 , severe infection Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive know suspect active hepatitis C infection A diagnosis treat another malignancy within 2 year first dose TAK960 previous diagnosis another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection Any serious medical psychiatric illness could potentially interfere completion treatment Recurrent nausea vomit requirement antiemetic therapy within 14 day first dose TAK960 Known gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerability TAK960 , include difficulty swallow capsule Treatment investigational product within 21 day first dose TAK960 Systemic use strong CYP3A inhibitor inducer within 14 day first dose TAK960 Patients enrol expansion cohort tumor biopsy require must meet additional criterion accord study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>